Anti-Mouse CD70 (Clone TAN1-7) – Purified in vivo PLATINUM™ Functional Grade

Recombinant mouse CD70 (extracellular domain, aa residues 41-195)

This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s Purified Functional PLATINUM^TM antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.

Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

Next Day 2-8°C

Clone TAN1-7 monoclonal antibody recognizes a direct epitope on mouse CD70 and capable of blocking the CD70-CD27 interaction involved in B and T cell activation.

CD70 is expressed on activated T cells, B cells, and dendritic cells.

CD70 antibody, TAN1-7, recognizes CD70, a type II membrane protein and member of the TNF family. CD70 is the ligand for the T cell costimulatory receptor CD27 (also known as TNFRSF27)¹ and is expressed on activated T cells, B cells, and dendritic cells (DCs)^1,2. Ligation of CD27 on T cells with CD70 on DCs provides costimulatory signals and promotes CD4 and CD8 T cell activation³, differentiation⁴, and survival^5,6. CD70 also regulates B cell activation and antibody production⁷ and enhances natural killer (NK) cell survival and function⁸. CD70 is constitutively expressed in several hematological and solid tumors and increases the proliferation and survival of tumor cells and regulatory T cells (Tregs), suggesting it may be an effective therapeutic target^9-13. Increased levels of CD70 are also associated with autoimmune disorders, including rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE)^14,15.

1. R. A. van Lier., et al. (1997) J. Immunol. 159(10):4959-65
2. R. A. van Lier. et al. (2003) J. Immunol. 170(1):33-40
3. Hintzen, R. Q. et al. (1995) J. Immunol. 154, 2612–2623
4. Soares, H. et al. (2007) J. Exp. Med. 204, 1095–1106
5. Hendriks, J. et al. (2000) Nat. Immunol.1, 433–440
6. Hendriks, J., Xiao, Y. & Borst, J. (2003) J. Exp. Med.198, 1369–1380
7. van Oers MH., et al. (2004) J Immunol. 15;173(6):3901-8. 8. Ochsenbein AF., et al. (2017) 20;130(3):297-309
9. Ansell SM., et al. (2007) Blood. 110:2537–2544
10. Doronina SO., et al. (2006) Cancer Res. 66:2328–2337
11. Weller M., et al. (2002) Cancer Res. 62:2592–2599
12. Held-Feindt, J. & R. Mentlein. (2002) Int. J. Cancer 98:352
13. Chiodi F., et al. (2005) Exp Hematol. 33:1500–1507
14. Han, B. K. et al. (2005) Lupus. 14, 598–606
15. Park, J. K. et al. (2014) Rheumatology. 53, 1896–1900